Table 2.
Five-year relative survival (standard error) in 2014–2018 by deprivation quintile, cancer site and subgroups.
| Site | Subgroup | Deprivation | Relative Excess Risk1 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Least (Q1) | Q2 | Q3 | Q4 | Most (Q5) | Q5-Q1 | Adjusted for: Age |
Adjusted for: Age+Stage |
||
| Colorectal | Colon2 | 74·2 (2·1) | 64·9 (2·3) | 63·9 (2·2) | 66 (2·3) | 63·7 (2·2) | −10·5 | 1·38 (1·12–1·71) | 1·16 (0·93–1·44) |
| Rectum [2] | 68·7 (3·1) | 64·4 (3·3) | 61·0 (3·1) | 57·6 (3·3) | 60·1 (3·0) | −8·6 | 1·24 (0·94–1·65) | 1·31 (0·97–1·78) | |
| 15–64 years | 77 (2·7) | 67·3 (3·0) | 68·3 (2·9) | 69·2 (3·1) | 68·5 (2·7) | −8·5 | 1·46 (1·05–2·02) | 1·43 (1·00–2·04) | |
| 65–74 years | 74·2 (3·2) | 64·2 (3·2) | 61·1 (3·0) | 60·3 (3·3) | 59·5 (3·2) | −14·7 | 1·65 (1·19–2·28) | 1·25 (0·89–1·75) | |
| 75+ years | 65·1 (3·6) | 63·6 (3·7) | 55·6 (3·3) | 57·8 (3·5) | 55·5 (3·5) | −9·6 | 1·11 (0·87–1·42) | 1·05 (0·81–1·35) | |
| Female2 | 70·8 (1·7) | 63·2 (1·8) | 61·0 (1·7) | 61·6 (1·8) | 60·1 (1·7) | −10·7 | 1·38 (1·08–1·78) | 1·19 (0·91–1·54) | |
| Male2 | 75·4 (1·8) | 67·5 (2·0) | 64·9 (1·8) | 65·6 (1·9) | 63·9 (1·8) | −11·5 | 1·31 (1·04–1·65) | 1·20 (0·94–1·53) | |
| Lung | 15–64 years | 22·5 (3·0) | 24·7 (2·5) | 17·0 (1·9) | 21·1 (2·2) | 19·1 (1·8) | −3·4 | 1·10 (0·91–1·33) | 1·04 (0·85–1·27) |
| 65–74 years | 20·4 (2·5) | 16·7 (2·0) | 15·0 (1·8) | 15·8 (1·9) | 16·7 (1·7) | −3·7 | 1·19 (1·01–1·40) | 1·29 (1·08–1·54) | |
| 75+ years | 10·5 (2·2) | 8·4 (1·8) | 5·2 (1·2) | 14·9 (2·3) | 9·8 (1·8) | −0·7 | 1·03 (0·87–1·21) | 0·97 (0·81–1·16) | |
| Female2 | 18·4 (2·1) | 19·0 (1·6) | 12·7 (1·1) | 16·5 (1·2) | 15·9 (1·2) | −2·5 | 1·07 (0·92–1·24) | 1·12 (0·95–1·31) | |
| Male2 | 19·4 (2·1) | 19·8 (1·7) | 13·3 (1·1) | 17·4 (1·3) | 16·7 (1·2) | −2·7 | 1·11 (0·98–1·28) | 1·06 (0·91–1·22) | |
| Breast | 15–64 years | 93·7 (1·0) | 92·4 (1·1) | 90·0 (1·2) | 89·5 (1·3) | 88·5 (1·3) | −5·2 | 1·90 (1·29–2·80) | 1·17 (0·80–1·70) |
| 65–74 years | 95·4 (1·7) | 90·3 (2·0) | 89·4 (2·2) | 91·5 (2·3) | 84·5 (2·6) | −10·9 | 3·47 (1·60–7·54) | 1·51 (0·92–2·47) | |
| 75+ years | 82·6 (3·5) | 81·6 (3·8) | 80·4 (3·7) | 80·0 (3·7) | 73·6 (3·9) | −9·0 | 1·57 (0·95–2·57) | 1·09 (0·70–1·68) | |
| Prostate | 15–64 years | 98·7 (1·6) | 95·2 (2·2) | 94·7 (2·1) | 90·3 (2·6) | 90·1 (2·3) | −8·6 | 5·44 (1·07–27·58) | 1·33 (0·58–3·04) |
| 65–74 years | 97·6 (1·8) | 94·0 (2·2) | 93·9 (2·2) | 90·0 (2·5) | 87·7 (2·5) | −9·9 | 5·77 (1·45–22·94) | 1·65 (0·85–3·20) | |
| 75+ years | 82·6 (4·2) | 71·3 (4·6) | 75·5 (3·9) | 73·1 (4·6) | 69·7 (4·6) | −12·9 | 2·15 (1·33–3·48) | 0·90 (0·60–1·36) | |
1
Relative excess risk and 95% confidence interval for Q5 versus Q1. Significant relative excess risks are printed in bold.
2
Age-standardized.